INKT — Mink Therapeutics Balance Sheet
0.000.00%
- $58.30m
- $49.75m
Annual balance sheet for Mink Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.69 | 38.9 | 19.6 | 3.37 | 4.58 |
| Net Total Receivables | 0.02 | 0.023 | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.1 | 39.6 | 20.4 | 3.6 | 4.99 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.458 | 0.607 | 1.07 | 0.954 | 0.733 |
| Total Assets | 4.56 | 40.2 | 21.5 | 4.55 | 5.72 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 14.2 | 16.5 | 12.7 | 11.4 | 6.96 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 58.4 | 16.5 | 21.9 | 22.6 | 25.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -53.9 | 23.8 | -0.401 | -18.1 | -19.6 |
| Total Liabilities & Shareholders' Equity | 4.56 | 40.2 | 21.5 | 4.55 | 5.72 |
| Total Common Shares Outstanding |